Artiva Biotherapeutics, INC Form 4 insider transactions

Artiva Biotherapeutics' COO, CLO, Secretary, and Compliance Officer, Jennifer Bush, disposed of 3,055 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Artiva Biotherapeutics' Chief Financial Officer, Neha Krishnamohan, reported the withholding of 3,490 common shares to cover tax obligations related to restricted stock unit vesting.

Artiva Biotherapeutics' President and CEO, Fred Aslan, reported sales of common stock totaling 12,722 shares, primarily for tax obligations and under a pre-arranged 10b5-1 trading plan.

Artiva Biotherapeutics' President and CEO, Fred Aslan, reported the sale of 25,500 shares of common stock at $6 per share, executed under a Rule 10b5-1 plan.

Artiva Biotherapeutics CEO Fred Aslan sold and had shares withheld to cover tax obligations related to restricted stock unit vesting.

Artiva Biotherapeutics' SVP of Research and Development, Heather Raymon, had shares withheld to cover tax obligations from restricted stock unit vesting.

Artiva Biotherapeutics' CFO, Neha Krishnamohan, reported changes in her beneficial ownership due to tax withholdings from vested restricted stock units.

An Artiva Biotherapeutics executive disposed of common stock to cover tax obligations from restricted stock unit vesting.

Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, reported share dispositions to cover tax obligations from restricted stock unit vesting.

A recent SEC Form 4 filing reveals that Laura Stoppel, a director of Artiva Biotherapeutics and partner at RA Capital Management, L.P., was granted 13,750 stock options with an exercise price of $1.61.

Artiva Biotherapeutics Director Alison Moore was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026.

Artiva Biotherapeutics, Inc. Director Daniel G. Baker was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026 or the 2026 annual stockholder meeting.

Artiva Biotherapeutics, Inc. Director Elizabeth L. Hougen was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026.

Artiva Biotherapeutics, Inc. Director Laura Stoppel was granted 13,750 stock options with an exercise price of $1.61, vesting by June 2026.

Artiva Biotherapeutics Director Diego Miralles Gines was granted 13,750 stock options with an exercise price of $1.61, aligning his incentives with shareholder value.

Artiva Biotherapeutics, Inc. Director Brian Daniels was granted 13,750 stock options with an exercise price of $1.61, vesting by June 24, 2026, or the 2026 annual stockholder meeting.

Subhashis Banerjee, Chief Medical Officer of Artiva Biotherapeutics, reports the acquisition of 50,000 shares of common stock and options to purchase 80,000 shares.

Fred Aslan, CEO of Artiva Biotherapeutics, reports acquisition and disposal of common stock and adjustment of restricted stock units.

Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, reports the acquisition of 33,350 shares of common stock on February 26, 2025, as a restricted stock unit award.

Thorsten Graef, Chief Medical Officer of Artiva Biotherapeutics, reports acquiring 60,000 shares of common stock and disposing of 80,000 shares.

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, reports the acquisition of 60,000 shares of common stock and disposal of shares.

Neha Krishnamohan, CFO of Artiva Biotherapeutics, reports the acquisition of 60,000 shares of common stock and disposal of 110,000 shares.

Jennifer Bush, COO, CLO, Secy, Compliance Off of Artiva Biotherapeutics, reports acquiring 86,650 shares of common stock and disposing of 159,449 shares on February 26, 2025.

Director Daniel G. Baker acquired 27,500 stock options in Artiva Biotherapeutics, Inc. on January 28, 2025, according to a Form 4 filing.

Alison Moore, a director at Artiva Biotherapeutics, acquired 27,500 shares via a stock option grant on October 21, 2024.

Heather Raymon, SVP of Research and Development at Artiva Biotherapeutics, reports the acquisition of 10,000 shares of common stock through a restricted stock unit award.

Thorsten Graef, Chief Medical Officer of Artiva Biotherapeutics, was granted 20,000 restricted stock units on September 12, 2024, under the company's 2024 Equity Incentive Plan.

Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, was granted 25,000 restricted stock units on September 12, 2024.

Neha Krishnamohan, CFO of Artiva Biotherapeutics, reports the acquisition of 50,000 shares of common stock on September 12, 2024, as part of a restricted stock unit award.

Jennifer Bush, COO, CLO, Secretary, and Compliance Officer of Artiva Biotherapeutics, reports acquiring 50,000 shares of common stock and disposing of 72,799 shares.